- supports partnership of InnoCyte and PharmaCell -
Stuttgart / Maastricht, January 21, 2015: InnoCyte and PharmaCell announced today that both companies are working together as partners to scientifically support InnoCyte’s product split.it, which is the first benchtop device worldwide for cell passage. Both companies will also investigate the options for further developing the technology platform of InnoCyte regarding GMP bioproduction and cell therapy. This cooperation has been developed in the scope of the Biomaterials Innovation Network Biomat-IN and is sponsored.
In reaction to the market requirements, InnoCyte follows a flexible, modular strategy: Benchtop devices are to close the gap between labor-intensive and error-prone manual laboratory tasks and the expensive, highly complex robot systems. This way, approx. 40,000 central labs all over the world will have the possibility to follow their own path regarding laboratory automation, and to develop new options regarding the certainty of results and productivity. The cell passage is a central labor-intensive routine step within the cell culture and, therefore, an ideal basis for the automated device solution split.it. For the first time, split.it offers cell laboratories an affordable solution for the implementation already starting with small and medium passage numbers.
“The production of cells and tissue for medical research and therapy is a promising future market. We are very satisfied that our cooperation as one of the worldwide leading suppliers is able to set important accents for bioproduction,” says Dr. Soenke Brunswiek, Director Business Development at PharmaCell. “Automation plays an important role for success here, i.e. in particular safety and efficiency.”
“Cooperation leads to innovation. The support of partnerships beyond national borders as in the example of InnoCyte and PharmaCell was the exact target of the Biomaterials Innovation Network Biomat-IN. We are therefore very pleased about this cooperation.” commented Dr. Klaus Eichenberg, Managing Director of the BioRegio STERN Management GmbH.
InnoCyte GmbH is a technology specialist for innovative device solutions and automation all about cell culture with applications in the pharmaceutical and biotechnological industry as well as regenerative medicine. InnoCyte pursues a flexible and modular product strategy: Benchtop devices close the gap between labor-intensive and error-prone manual laboratory tasks and the expensive, complex robot systems. It is in this way that InnoCyte enables approximately 40,000 cell culture laboratories worldwide to choose their own path in laboratory automation and opens up new horizons for growth. InnoCyte is a spin-off of the Fraunhofer Gesellschaft.
PharmaCell is the leading European contract manufacturer (CMO) in the field of human cell therapy and regenerative medicine. PharmaCell has experience in supporting clinical phase I-III trials and commercialization projects regarding production, quality control (QC), quality testing (QT), batch certification, storage, and inbound and outbound logistics. The company offers contract services exclusively in the field of human cell therapy and regenerative medicine. Services include the process and assay development up to the GMP compliance as well as the guarantee of robust and scalable manufacturing processes. PharmaCell operates two state-of-the-art, cGMP-certified production plants in Maastricht, in the Netherlands, in the middle of Europe. The plants comprise 4,500 m2 including clean rooms of the classes A, B, C, and D (class 100/10,000/100,000), laboratories for research and development as well as quality control (QC), the cryoconservation, storage and logistic surfaces.
The Biomaterials Innovation Network Biomat-IN includes five European BioRegions pooling their resources in an international network to support innovations in the field of biomaterials by way of transnational cooperation. Eurasanté and Atlanpole Biotherapies in France, BioRegio STERN Management GmbH in Germany, Medilink EM in Great Britain, and LIOF in the Netherlands. This progress in biotechnology, cell and tissue technique, and polymer chemistry requires the application of innovative biomaterials as well as new strategies for multidisciplinary research implemented by scientists and industrial partners.
Roland Huchler, +49 (0)176 200 601 06, email@example.com
CEO and founder of InnoCyte GmbH
Je moet ingelogd zijn om te kunnen reageren.